Objective To provide first real-world experience on patients with MS treated with the B cell–depleting antibody ocrelizumab. Methods We retrospectively collected data of patients who had received at least 1 treatment cycle (2 infusions) of ocrelizumab at 3 large neurology centers. Patients’ characteristics including premedication, clinical disease course, and documented side effects were…
As part of our “Physician as Patient” series, Dr. Andy Southerland talks with Dr. Amy Hessler about her experience with a ruptured arteriovenous malformation as…
A 57-year-old male patient developed within 2 weeks rapid progressive gait instability, memory deficits, hypomania, and recurrent complex tic-like involuntary outbursts of vocalization 15 and…
Background and ObjectivesFew anecdotal cases and 1 small retrospective study during short-duration space missions suggest that headache may occur early in flight, as part of…
Submission guidelines and manuscript categories for Neurology Journals.
We invite applications for the position of Editor of Neurology ® Genetics. The position will become available when the editorial term of Stefan Pulst, MD,…
Background and ObjectivesInverse associations between caffeine intake and Parkinson disease (PD) have been frequently implicated in human studies. However, no studies have quantified biomarkers of…
Background and ObjectivesProspective measures of plasma and cerebral MRI biomarkers of Alzheimer disease (AD) and vascular neuropathology provide an opportunity to investigate possible mechanisms linking…
NO PURCHASE IS NECESSARY TO ENTER OR WIN. You are providing your information to the American Academy of Neurology (“Sponsor”). Any questions, comments or complaints…
Submission guidelines and manuscript categories for Neurology Journals.
